Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Trastuzumab emtansine improves progression-free survival for HER2-positive breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 03.06.12
Views: 3711
Rating:

Dr Kimberly Blackwell - Duke University Medical Center, Durham, USA

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Kimberly Blackwell presented on a phase III randomised study, EMILIA, of the investigational agent trastuzumab emtansine (T-DM1) vs. standard therapy using capecitabine and lapatinib.

 

Dr Blackwell and her team found significant and clinically meaningful improvement in progression-free survival with T-DM1 in women with HER2-positive locally advanced or metastatic breast cancer previously treated with a taxane and trastuzumab. 

 

Related videos

follow us

WIN 2019


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation